EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY 4.0

Risk of ischemic stroke associated with anti-rheumatic agents in patients with rheumatoid arthritis: A nationwide population-based case-control study

Risiko für ischämischen Schlaganfall unter antirheumatischen Wirkstoffen bei Patient:innen mit rheumatoider Arthritis: landesweite populationsbasierte Fall-Kontroll-Studie

Soo Min Ahn, Seonok Kim iD, Ye-Jee Kim iD, Seokchan Hong, Chang-Keun Lee, Bin Yoo, Ji Seon Oh iD, Yong-Gil Kim iD

PLOS One · 17.06.2025 · 20 (6) · e0326311

DOI: 10.1371/journal.pone.0326311 ↗

Auf einen Blick

In einer koreanischen Fall-Kontroll-Studie war die aktuelle Exposition gegenüber Sulfasalazin und Hydroxychloroquin mit einem geringeren Schlaganfallrisiko verbunden. Glukokortikoide und Tocilizumab waren mit einem höheren Risiko assoziiert.

Fragestellung

Wie ist die Anwendung verschiedener antirheumatischer Wirkstoffe bei Patient:innen mit rheumatoider Arthritis mit dem Risiko eines erstmaligen Schlaganfalls verbunden?

Methode

Nested Fall-Kontroll-Studie mit koreanischen Abrechnungsdaten; 35.133 neu diagnostizierte seropositive RA-Patient:innen von Januar 2011 bis Dezember 2020; 1:4-Matching; konditionale logistische Regression.

Ergebnisse

35.133 Patient:innen, davon 1.384 Schlaganfallfälle und 5.499 Kontrollen in der Analyse. Aktuell: Sulfasalazin aOR 0,79 (95 %-KI 0,65–0,97), Hydroxychloroquin aOR 0,83 (95 %-KI 0,72–0,96), Glukokortikoide aOR 1,71 (95 %-KI 1,46–2,00), Tocilizumab aOR 3,47 (95 %-KI 1,70–7,08).

Einschränkungen

Der Zusammenhang mit Tocilizumab sollte wegen statistischer Einschränkungen vorsichtig interpretiert werden.

Schlussfolgerung der Autor:innen

Bei RA war Sulfasalazin und Hydroxychloroquin mit geringerem Schlaganfallrisiko verbunden, Glukokortikoide und Tocilizumab mit höherem Risiko. Der Zusammenhang mit Tocilizumab ist vorsichtig zu bewerten.

Kernaussagen

  • Sulfasalazin: niedrigeres Schlaganfallrisiko
  • Hydroxychloroquin: niedrigeres Schlaganfallrisiko
  • Glukokortikoide und Tocilizumab: höheres Schlaganfallrisiko

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift PLOS One, online erschienen am 17.06.2025. Verfasst von Soo Min Ahn und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Ischemic Stroke. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCIRD CDC HHS, Korea Health Industry Development Institute, Asan Institute for Life Sciences, Asan Medical Center.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patients with rheumatoid arthritis (RA) face a significantly higher risk of major adverse cardiovascular events, including stroke, due to the pivotal role of inflammation in atherosclerosis and thrombosis. Various anti-rheumatic agents may influence stroke risk either by increasing or decreasing it, and this effect remains unclear. This study aimed to investigate the association between different anti-rheumatic agents and the risk of incident stroke in patients with RA using a nationwide claims database.

Methods

In this nested case-control study, the Korean Health Insurance Review and Assessment data of 35,133 patients newly diagnosed with seropositive RA from January 2011 to December 2020 were used. Incident ischemic stroke cases were identified and matched with randomly selected controls at a 1:4 ratio. The usage of anti-rheumatic agents was measured from the date of RA diagnosis to the index date and stratified in terms of exposure time and duration. The risk of stroke associated with each anti-rheumatic agent was estimated using conditional logistic regression and adjusted for comorbidities and concomitant drug use.

Results

Of the 35,133 patients, 1,386 (3.9%) cases were newly diagnosed with new-onset stroke. Thus, 1,384 stroke cases and 5,499 controls with newly diagnosed RA were included in the analysis. Current exposure to sulfasalazine (aOR: 0.79, 95% CI: 0.65–0.97) and hydroxychloroquine (aOR: 0.83, 95% CI: 0.72–0.96) was associated with a decreased risk of stroke, while current exposure to glucocorticoids (aOR: 1.71, 95% CI: 1.46–2.00) and tocilizumab (aOR: 3.47, 95% CI: 1.70–7.08) was related to an increased risk of stroke.

Conclusion

In this nationwide cohort study of patients with RA, treatment with sulfasalazine and hydroxychloroquine was associated with a decreased risk of stroke, while glucocorticoids and tocilizumab were linked to an increased risk of stroke. The association of tocilizumab with stroke should be cautiously interpreted due to the statistical limitations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsIschemic StrokeHumansMaleFemaleCase-Control StudiesMiddle AgedAgedRisk FactorsAdultRepublic of KoreaHydroxychloroquineSulfasalazine

Substanzen

Antirheumatic AgentsHydroxychloroquineSulfasalazine

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea.

ORCID-Profile: Seonok Kim, Ye-Jee Kim, Ji Seon Oh, Yong-Gil Kim

Förderung

  • NCIRD CDC HHS
  • Korea Health Industry Development Institute
  • Asan Institute for Life Sciences, Asan Medical Center

Zitieren

APA

Ahn, S. M., Kim, S., Kim, Y. J., Hong, S., Lee, C. K., Yoo, B., Oh, J. S., & Kim, Y. G. (2025). Risk of ischemic stroke associated with anti-rheumatic agents in patients with rheumatoid arthritis: A nationwide population-based case-control study. PLOS One, 20(6), e0326311. https://doi.org/10.1371/journal.pone.0326311

Vancouver

Ahn SM, Kim S, Kim YJ, Hong S, Lee CK, Yoo B, et al. Risk of ischemic stroke associated with anti-rheumatic agents in patients with rheumatoid arthritis: A nationwide population-based case-control study. PLOS One. 2025;20(6):e0326311. doi:10.1371/journal.pone.0326311

BibTeX
@article{Ahn2025,
  author = {Ahn, Soo Min and Kim, Seonok and Kim, Ye-Jee and Hong, Seokchan and Lee, Chang-Keun and Yoo, Bin and Oh, Ji Seon and Kim, Yong-Gil},
  title = {Risk of ischemic stroke associated with anti-rheumatic agents in patients with rheumatoid arthritis: A nationwide population-based case-control study},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {6},
  pages = {e0326311},
  doi = {10.1371/journal.pone.0326311}
}
Kostenlos starten →